DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
7.08
+0.07 (1.00%)
At close: Jul 21, 2026, 4:00 PM EDT
7.08
0.00 (0.00%)
After-hours: Jul 21, 2026, 4:10 PM EDT
DiaMedica Therapeutics Employees
DiaMedica Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 7 or 25.00% compared to the previous year.
Employees
35
Change (1Y)
7
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,002,886
Market Cap
381.49M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 7 | 25.00% | 35 | 0 |
| Dec 31, 2024 | 28 | 9 | 47.37% | 27 | 1 |
| Dec 31, 2023 | 19 | 3 | 18.75% | 18 | 1 |
| Dec 31, 2022 | 16 | 1 | 6.67% | 16 | 0 |
| Dec 31, 2021 | 15 | 4 | 36.36% | 14 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 754 |
| Abeona Therapeutics | 226 |
| Rocket Pharmaceuticals | 202 |
| Sutro Biopharma | 133 |
| Enanta Pharmaceuticals | 120 |
| Prelude Therapeutics | 79 |
| Upstream Bio | 75 |
| Lexeo Therapeutics | 59 |
DMAC News
- 4 days ago - DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - DiaMedica Therapeutics announces dosing of first two patients in DM199 study - TheFly
- 4 weeks ago - DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
- 5 weeks ago - DiaMedica Therapeutics receives written response from FDA on DM199 - TheFly
- 5 weeks ago - DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program - Business Wire
- 7 weeks ago - DiaMedica Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 - Business Wire
- 2 months ago - DiaMedica announces 75% enrollment milestone in ReMEDy2 Phase 2/3 trial - TheFly